Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697119 | 0.90 | TYK2 (0.44) | TYK2RIPK3METRIPK2 | |
| SCHEMBL20697113 | 0.89 | TYK2 (0.57) | TYK2 | |
| SCHEMBL20689403 | 0.88 | TYK2 (0.58) | TYK2 | |
| SCHEMBL20689401 | 0.80 | TYK2 (0.54) | TYK2 | |
| SCHEMBL20689402 | 0.79 | TYK2 (0.70) | TYK2 | |
| SCHEMBL21227563 | 0.75 | TYK2 (0.68) | TYK2 | |
| SCHEMBL20697404 | 0.73 | TYK2 (0.52) | TYK2 | |
| SCHEMBL20689031 | 0.72 | TYK2 (0.51) | TYK2 | |
| SCHEMBL20689507 | 0.71 | TYK2 (0.48) | TYK2 | |
| SCHEMBL362582 | 0.62 | LMNA (0.57) | RIPK3METRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885RIPK3 183/4885MET 3604/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885RIPK3 183/4885MET 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.